Ophthalmology Retina
Outcomes of High-Dose Aflibercept in Exudative nAMD
Bala S, Barbosa GCS, Mohan N, et al
In this retrospective, noncomparative cohort study, the authors evaluated short-term outcomes of patients with exudative neovascular age-related macular degeneration treated with aflibercept 8 mg. Stable BCVA and significant reductions in macular fluid were seen during the follow-up period. These findings suggest that aflibercept 8 mg maintains functional stability while improving anatomic outcomes.
Previous Article
- • Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration
- • Real-World Safety and Efficacy of 8 mg Aflibercept in nAMD
- • Case Report: Aflibercept for DME in Vitrectomized Eyes
- • Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
- • AI-Assisted Fluid Volume Analysis of Treatment-Naive nAMD in the Real World
- • Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
- • Outcomes of High-Dose Aflibercept in Exudative nAMD
- • PULSAR: Intravitreal Aflibercept 8 mg in nAMD
- • PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
- • CANDELA: Aflibercept 8 mg in Patients With nAMD
